v3.26.1
Segment Information (Details)
3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | segment 1  
Segment Reporting Information [Line Items]    
Revenue from collaborative arrangement $ 0 $ 65,343
Less:    
Research and development expenses 14,070,107 16,090,902
General and administrative 7,879,886 9,024,970
Total operating expenses 21,949,993 25,115,872
Interest income 439,593 808,077
Change in fair value of common stock warrant liabilities 4,137,703 3,712,872
(Loss) gain on investment in affiliated entity (2,103,688) 695,131
Net unrealized gain on available-for-sale equity securities 79,077 140,234
Other expense, net (285,490) (482)
Net loss (19,682,798) (19,694,697)
INO-3107    
Less:    
Research and development expenses 4,005,292 3,507,342
INO-3112 And Other Immuno-oncology    
Less:    
Research and development expenses 365,228 684,449
Other programs    
Less:    
Research and development expenses 1,083,283 738,060
Engineering and device-related    
Less:    
Research and development expenses 4,041,116 5,061,810
Stock-based compensation    
Less:    
Research and development expenses 276,912 553,394
Other unallocated expenses    
Less:    
Research and development expenses 4,298,276 5,545,847
Reportable Segments    
Segment Reporting Information [Line Items]    
Revenue from collaborative arrangement 0 65,343
Less:    
General and administrative 7,879,886 9,024,970
Total operating expenses 21,949,993 25,115,872
Interest income 439,593 808,077
Change in fair value of common stock warrant liabilities (4,137,703) (3,712,872)
(Loss) gain on investment in affiliated entity (2,103,688) 695,131
Net unrealized gain on available-for-sale equity securities 79,077 140,234
Other expense, net (285,490) (482)
Net loss $ (19,682,798) $ (19,694,697)